Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. April 2025 16:05 ET | Quelle: Tvardi Therapeutics

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi shares to begin...
19. März 2025 08:00 ET | Quelle: Tvardi Therapeutics

Tvardi Therapeutics Announces Publication of Results from First-in-Human Study of TTI-101 in Patients with Advanced Solid Tumors in the Journal Clinical Cancer Research

Tvardi’s previously announced merger with publicly traded Cara Therapeutics is on-track to close in 1H 2025 TTI-101 is currently being evaluated in a Phase 2 study in patients with idiopathic...
19. Februar 2025 08:30 ET | Quelle: Tvardi Therapeutics

Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

HOUSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies...